CancerAI-SCPNCT07700199
AI-Driven Survivorship Care Plans (AI-SCP)
A study testing SCP Chatbot in people with Cancer, run by University of Utah at 1 site in United States.
Trial summary
This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electronic health record (EHR) data to automate the development of tailored SCPs, paired with a patient-facing chatbot to answer questions about the SCP. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- SCP Chatbot
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult cancer survivors
- Age +18 years,
- Speak and understand English
- Affiliated with the Huntsman Cancer Institute.
Who cannot join
- Under age 18
- Not affiliated with Huntsman Cancer Institute
- Unable to speak or understand English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Utah
Salt Lake City, Utah, 84112
Echo Warner, MPH, PhD, SB, 801-244-7040, u0600488@umail.utah.edu
Echo Warner, MPH, PhD, SB
About this study
This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electronic health record (EHR) data to automate the development of tailored SCPs, paired with a patient-facing chatbot to answer questions about the SCP. Unlike generic AI documentation tools, this system establishes benchmarks for SCP development and embeds user-centered design (UCD) directly into prompt engineering and model governance workflows.
- Conditions
- Cancer
- Being tested
- SCP Chatbot
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SCP ChatbotOther
Also called GARDE-Chat
A secure LLM pipeline with structured and unstructured EHR data to automatically generate Survivorship Care Plans (SCPs) and develop a patient-facing chatbot to support comprehension.
The SCP chatbot will leverage GARDE-Chat, an NCI-funded open-source chatbot platform
| Study group | Role | What they receive |
|---|---|---|
| SCP Chatbot | Other | Participants will receive an AI-SCP and access to the SCP chatbot from an oncologist for 7 days . Receives: Other: SCP Chatbot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility: Recruitment Retention
Feasibility of the interactive AI-SCP and chatbot. This outcome measure will report the proportion of subjects who were retained from recruitment.
Measured: up to 7 days
Secondary outcomes (1)
Acceptability/Usability: System Usability Scale
Acceptability and usability of the interactive AI-SCP and chatbot. This outcome measure will report the mean System Usability Scale (SUS) score. SUS scores range from 0-100, with higher scores indicating better usability and lower scores indicating worse usability.
Measured: up to 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study startNov 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- Huntsman Cancer Institute
- Responsible party
- Sponsor
- Investigators
- Echo Warner, MPH, PhD, SB, Principal investigator, Huntsman Cancer Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07700199
- Sponsor's protocol ID
- 201667
- Acronym
- AI-SCP
- Status last verified
- Jul 2026
- First submitted
- 7 Jul 2026
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- AI-Driven Survivorship Care Plans (AI-SCP)
- ClinicalTrials.gov ID
- NCT07700199
- Acronym / sponsor ID
- AI-SCP / 201667
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- Huntsman Cancer Institute
- Study start
- Nov 2026 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electronic health record (EHR) data to automate the development of tailored SCPs, paired with a patient-facing chatbot to answer questions about the SCP. Unlike generic AI documentation tools, this system establishes benchmarks for SCP development and embeds user-centered design (UCD) directly into prompt engineering and model governance workflows.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SCP Chatbot | Other | Other: SCP ChatbotParticipants will receive an AI-SCP and access to the SCP chatbot from an oncologist for 7 days . |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult cancer survivors
- Age +18 years,
- Speak and understand English
- Affiliated with the Huntsman Cancer Institute.
Key exclusion criteria (3 listed)
- Under age 18
- Not affiliated with Huntsman Cancer Institute
- Unable to speak or understand English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SCP ChatbotAlso: GARDE-ChatA secure LLM pipeline with structured and unstructured EHR data to automatically generate Survivorship Care Plans (SCPs) and develop a patient-facing chatbot to support comprehension. The SCP chatbot will leverage GARDE-Chat, an NCI-funded open-source chatbot platform | Other | SCP Chatbot |
Primary outcome
Feasibility: Recruitment Retention
Time frame: up to 7 days
Feasibility of the interactive AI-SCP and chatbot. This outcome measure will report the proportion of subjects who were retained from recruitment.
1 secondary outcome
Acceptability/Usability: System Usability Scale
Time frame: up to 7 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruiting
Using e-Technologies to Maximize Physical Activity After Cancer Treatment
Cancer
RecruitingPhase 1
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors
Relapsed Solid Tumor Malignancies, Refractory Solid Tumor Malignancies
RecruitingObservational study
Pharmacogenetic Determinants Of Treatment Response In Children
All Malignancies, Children Being Treated for Catastrophic Illness
RecruitingObservational study
Cancer in Inherited Bone Marrow Failure Syndromes
Diamond Blackfan Anemia, Dyskeratosis Congenita
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Echo Warner, MPH, PhD, SB principal investigator
Huntsman Cancer Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SCP Chatbot in people with Cancer, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Echo Warner, MPH, PhD, SB (801-244-7040, echo.warner@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility: Recruitment Retention (time frame: up to 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.